You just read:

OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma

News provided by

OncoSec Medical Incorporated

10 May, 2017, 06:00 ET